Senesco Expands On Recently Announced Preclinical Pancreatic Islet Data

Senesco Technologies, Inc. (”Senesco” or the “Company”) (Amex: SNT) announced further details of Dr. Raghavendra Mirmira’s preclinical pancreatic islet cell research that was funded by the Company. Using a small interfering RNA (siRNA) against Senesco’s Factor 5A technology, the data show what we believe to be a variety of promising results regarding delivery of the technology as well as islet function and protection.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 17th, 2008